Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study.
Journal: Human vaccines & immunotherapeutics
Published: July 13, 2026
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial.
Journal: The Lancet. Infectious diseases
Published: October 15, 2025
The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With Naloxone.
Journal: Clinical and translational science
Published: July 29, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.
Journal: Human vaccines & immunotherapeutics
Published: April 02, 2025
Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study.
Journal: Frontiers in immunology
Published: September 24, 2024
Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.
Journal: The Lancet. Infectious diseases
Published: February 27, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.
Journal: NPJ vaccines
Published: October 23, 2023
Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.
Journal: The Journal of infectious diseases
Published: August 29, 2023
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
Journal: Vaccine
Published: August 25, 2023
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Journal: The Lancet. Infectious diseases
Published: June 12, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Journal: Open forum infectious diseases
Published: April 05, 2023
Last Updated: 09/26/2026